Israeli medical device company Keystone Heart has initiated the Phase II clinical trial (REFLECT) of its TriGUARD 3 Cerebral Embolic Protection device with the enrolment of the first subject.

TriGuard devices are designed to protect brain reserve from emboli while performing TAVR, surgical valve replacement, atrial fibrillation ablation and other cardiovascular procedures.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This protection is intended to minimise the risk of brain infarcts, stroke and cerebral damage.

“Expected to be completed in October this year, the REFLECT trial follows a Phase I study conducted in 258 patients using the TriGuard HDH device, which gained the European CE-Mark.”

The multi-centre, prospective, randomised REFLECT trial will assess the safety and efficacy of the third generation TriGUARD 3 device in around 275 patients.

This clinical study is primarily meant to validate the role of comprehensive cerebral embolic protection to improve the safety during the TAVR procedure.

Keystone Heart president and CEO Chris Richardson said: “We believe that it is imperative to bring a cerebral embolic protection device to the market that: protects all areas of the brain while minimising device interaction; avoids any manipulation of the arch vessels or an additional access site; is anatomy independent for universal patient application; and comes at a price point that will allow broad adoption for the majority of TAVR patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Expected to be completed in October this year, the REFLECT trial follows a Phase I study conducted in 258 patients using the TriGuard HDH device, which gained the European CE-Mark.

Data revealed that brain protection with TriGuard HDH significantly decreased the rate of VARC 2 defined strokes at 30 days and worsening of neurological findings NIHSS. The trial also found a higher incidence of ‘totally clean brains’.